CollPlant Biotechnologies (CLGN) Non-Current Deffered Revenue (2018)
CollPlant Biotechnologies (CLGN) reported Non-Current Deffered Revenue of $980000.0 for Q4 2018.
CollPlant Biotechnologies (CLGN) Non-Current Deffered Revenue (2018) Analysis & Trends
CollPlant Biotechnologies has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $980000.0 in Q4 2018.
- For the quarter ending Q4 2018, Non-Current Deffered Revenue changed N/A year-over-year to $980000.0; the trailing twelve-month figure through Dec 2018 stood at $980000.0 (changed N/A YoY), and the FY2018 full-year result was $980000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q4 2018 stood at $980000.0.
- The five-year high for Non-Current Deffered Revenue was $980000.0 in Q4 2018, with the low at $980000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | CollPlant Biotechnologies | 7.20 Mn | 7.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 980,000.00 |